THE USE OF BIOPROSTHETIC HEART VALVE IN A REPRODUCTIVE-AGED FEMALE PATIENT WITH ACQUIRED HEART DISEASE. SPECIFIC FEATURES OF DELIVERY


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The need for surgical correction of acquired heart disease in reproductive-aged women who plan future pregnancy requires a weighted assessment in choosing an implantable device in terms of the known advantages and disadvantages of different types of prosthetic heart valves. The use of biological prosthetic heart valves in this case is most preferred in spite of their limited functional lifespan since this makes it possible to refuse life-long anticoagulant therapy and to bear a healthy baby. In addition, bioprosthetic heart valve implantation in women of childbearing age requires no close monitoring of hemocoagulation parameters during pregnancy and labor or is not followed by an increased risk of uterine bleeding. A case of KemCor biological prosthesis implantation in a young woman with two previous pregnancies and deliveries is considered.

全文:

受限制的访问

作者简介

N. RUTKOVSKAYA

Research Institute of Complex Problems of Cardiovascular Diseases, Siberian Branch, Russian Academy of Medical Sciences

Email: wenys@mail.ru

N. ARTYMUK

Kemerovo State Medical Academy

Email: artymuk@gmail.com
Obstetrics and Gynecology Department Two

A. STASEV

Research Institute of Complex Problems of Cardiovascular Diseases, Siberian Branch, Russian Academy of Medical Sciences

Email: astasev@gmail.com

Yu. ODARENKO

Research Institute of Complex Problems of Cardiovascular Diseases, Siberian Branch, Russian Academy of Medical Sciences

Email: odarun2@mail.ru

Yu. SAVOSTYANOVA

Research Institute of Complex Problems of Cardiovascular Diseases, Siberian Branch, Russian Academy of Medical Sciences

Email: ulisys@mail.ru

I. SIZOVA

Research Institute of Complex Problems of Cardiovascular Diseases, Siberian Branch, Russian Academy of Medical Sciences

Email: swetlana.sap2@mail.ru

O. BARBARASH

Research Institute of Complex Problems of Cardiovascular Diseases, Siberian Branch, Russian Academy of Medical Sciences

参考

  1. Thiene G., Valente M. Anticalcification strategies to increase bioprosthetic valve durability. J. Heart Valve Dis. 2011; 20(1): 37-44.
  2. Tillquist M.N., Maddox T.M. Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement. Patient Prefer. Adherence. 2011; 5: 91-9.
  3. Butchart E.G. Antithrombotic management in patients with prosthetic valves: a comparison of American and European guidelines. Heart. 2009; 95(5): 430-6.
  4. Bloomfield P. Choice of heart valve prosthesis. Heart. 2002; 87(6): 583-9.
  5. Kulik A., Rubens F.D., Wells P.S., Kearon C., Mesana T.G., van Berkom J., Lam B.K. Early postoperative anticoagulation after mechanical valve replacement: a systematic review. Ann. Thorac. Surg. 2006; 81(2): 770-81.
  6. Otto C.M., Bonow R. O. Valvular heart disease a companion to Braunwald’s heart disease. Philadelphia: Saunders Elsevier; 2009.
  7. Pieper P.G., Balci A., Van Dijk A.P. Pregnancy in women with prosthetic heart valves. Neth. Heart J. 2008; 16(12): 406-11.
  8. Oakley R.E., Kleine P., Bach D.S. Choice of prosthetic heart valve in today’s practice. Circulation. 2008; 117(2): 253-6.
  9. DiSaila P. Pregnancy and delivery of a patient with Starr-Edwards mitral valve prosthesis: report of case. Obstet. Gynecol. 1966; 28: 469-72.
  10. Hall J.G. Embryopathy associated with oral anticoagulant therapy. Birth Defects Orig. Artic. Ser. 1976; 12(5): 33-7.
  11. Sillesen M., Hjortdal V., Vejlstrup N., S0rensen K. Pregnancy with prosthetic heart valves - 30 years’ nationwide experience in Denmark. Eur. J. Cardiothorac. Surg. 2011; 40(2): 448-54.
  12. Hung L., Rahimtoola S.H. Prosthetic heart valves and pregnancy. Circulation. 2003; 107(9): 1240-6.
  13. Ben Ismail M., Abid F., Trabelsi S., Taktak M., Fekih M. Cardiac valve prostheses, anticoagulation, and pregnancy. Br. Heart J. 1986; 55(1): 101-5.
  14. Salazar E., Izaguirre R., Verdejo J., Mutchinick O. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J. Am. Coll. Cardiol. 1996; 27(7): 1698-703.
  15. Окли С., Уоренс К.А. Заболевания сердца у беременных: Пер. с англ. Поздняков Ю.М., Л.Е. Мурашко Л.Е., ред. М: БИНОМ; 2010. 368 c.
  16. Oakley C.M. Anticoagulants in pregnancy. Br. Heart J. 1995; 74(2): 107-11.
  17. Oakley C.M. Clinical and pregnancy perspectives: anticoagulation. Eur. Heart J. 1995; 16: 1317-9.
  18. Borger M.A., Ivanov J., Armstrong S., Christie-Hrybinsky D., Feindel C.M., David T.E. Twenty-year results of the Hancock II bioprosthesis. J. Heart Valve Dis. 2006; 15(1): 49-55; discussion: 55-6.
  19. Pibarot P., Dumesnil J.G. Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation. 2009; 119(7): 1034-48.
  20. Караськов А.М., Назаров В.М., Железнев С.И. Дисфункции искусственных клапанов сердца. Новосибирск; 2008.
  21. Manji R.A., Zhu L.F., Nijjar N.K., Rayner D.C., Korbutt G.S., Churchill T.A. et al. Glutaraldehyde-fixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection. Circulation. 2006; 114(4): 318-27.
  22. Барбараш Л.С., Барбараш О.Л., Журавлева И.Ю. Биопротезы клапанов сердца: проблемы и перспективы. Кемерово; 1995.
  23. Jamieson W.R., Burr L.H., Munro A.I., Miyagishima R.T. Carpentier-Edwards standard porcine bioprosthesis: a 21-year experience. Ann. Thorac. Surg. 1998; 66(6,Suppl.1): S40-3.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2013